Importance of biologic status to the postoperative prognosis of patients with stage III nonsmall cell lung cancer

✍ Scribed by Dr. Kazuya Nakahara; Yasumasa Monden; Kiyoshi Ohno; Yoshitaka Fujii; Junpei Hashimoto; Youichiro Kitagawa; Yasunaru Kawashima

• Publisher: John Wiley and Sons
• Year: 1987
• Tongue: English
• Weight: 514 KB
• Volume: 36
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/jso.2930360302

✦ Synopsis

The prognosis of patients with stage 111 nonsmall cell lung cancer was studied, with special attention to their biologic status prior to lung resection. The biologic status was estimated from the neutrophil /lymphocyte ratio in the peripheral blood, serum albumin level, and erythrocyte sedimentation rate. Among 46 patients who underwent potentially curative operations, 31 cases of biologic status A or B (more than two parameters normal) revealed 37.6% of a 5-year survival rate, whereas there was no 5-year survivor in 15 cases of biologic status C or D (more than two parameters abnormal). Of the 5-year survival rate in T3No disease of biologic status A or B, the 60% surviving (of 10 cases) was in marked contrast to the same stage disease of biologic status C or D where only 1 patient (of 10 cases) was still surviving at more than 30 months. In 30 patients with T3N0, T3N1, and T2N2 diseases of biologic status A or B, where long-term survivors were derived, the 5-year survival rate in 30 patients of biologic status A or B was 36.6% in contrast to no long-term survivor in the same stage diseases of biologic status C or D (n = 25). We conclude that surgical results in stage 111 nonsmall cell lung cancer will be beneficial in patients of biologic status A or B, but nonbeneficial in patients with the same stage of biologic status C or D.